Trial Profile
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Safety and Efficacy of Secukinumab 300 mg and 150 mg in Adult Patients With Active Psoriatic Arthritis After 16 Weeks of Treatment Compared to Placebo and to Assess the Safety, Tolerability and Efficacy up to 52 Weeks
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 22 Apr 2022
Price :
$35
*
At a glance
- Drugs Secukinumab (Primary)
- Indications Psoriatic arthritis
- Focus Therapeutic Use
- Acronyms CHOICE
- Sponsors Novartis
- 15 Apr 2022 Results published in The Journal of Rheumatology
- 10 Jun 2019 Status changed from active, no longer recruiting to completed.
- 13 Feb 2018 Planned number of patients changed from 250 to 258.